Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2013

View Archived Issues

Novel therapy discovered for X-linked adrenoleukodystrophy

Cell therapy leads to improvements in spinal cord injury patient

AstraZeneca discovers novel PET radioligands that selectively bind to H3 receptors

New MJFF grant to support development of ND-0612

Fujifilm and Dr. Reddy's cancel partnership for generic drugs in Japan

Actelion Pharmaceuticals patents novel agents for bacterial infections

New mouse model of dominant uveal coloboma presented at ARVO

Sanofi updates on phase III iniparib and otamixaban studies

Fujifilm begins phase I study of anticancer agent in Japan

GSK reports phase III data for lapatinib plus chemotherapy in gastric cancer

GlaxoSmithKline to develop and commercialize MOR-103

Lambrolizumab shows significant activity and durable response in patients with melanoma

Natrogen Therapeutics International presents in vivo results for promising novel SLE therapy

FDA grants orphan drug status to ibrutinib, diazepam auto-injector and abatacept

Merck & Co. patents new series of DGAT1 inhibitors

Novel EZH2 inhibitors presented by Constellation Pharmaceuticals

Purdue Pharma divulges novel Na(V)1.7 channel blockers

Novel GPR119 receptor agonists patented by Array BioPharma

AstraZeneca to return rights to RA candidate following phase III results

AbbVie patents new Nampt inhibitors

Autifony commences phase I study of drug for treatment of hearing loss and tinnitus

FDA grants priority review to Bristol-Myers Squibb and AstraZeneca's metreleptin

FDA clears Kinex Pharmaceuticals' IND for KX-02

La Jolla Pharmaceutical submits IND to the FDA for LJPC-501

Naurex begins phase I trial of antidepressant agent NRX-1074

Octapharma submits MAA to the EMA for human recombinant coagulation factor VIII

Zeria and Astellas set to launch functional dyspepsia treatment Acofide in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...